Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 18/20 | 0.88 |
| ▸ | PDE6D | O43924 | 3/20 | 0.62 |
| ▸ | PDE6A | P16499 | 3/20 | 0.62 |
| ▸ | PDE6G | P18545 | 3/20 | 0.62 |
| ▸ | PDE6B | P35913 | 3/20 | 0.62 |
| ▸ | PDE6C | P51160 | 3/20 | 0.62 |
| ▸ | PDE6H | Q13956 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185512 | 0.95 | PDE5A (0.88) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7167116 | 0.93 | PDE5A (0.85) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL4993052 | 0.93 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7898479 | 0.93 | PDE5A (0.84) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7896528 | 0.91 | PDE5A (0.79) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL867299 | 0.91 | PDE5A (0.81) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7159428 | 0.91 | PDE5A (0.81) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7889440 | 0.90 | PDE5A (0.80) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7164781 | 0.90 | PDE5A (0.71) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL4986344 | 0.88 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225128-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BI YINGZHI (US) | 2003-12-04 | — | — | US | claimed |
| US-6576644-B2 | Treating sexual dysfunction including erectile dysfunction, diabetes melitus, gastrointestinal disorders, including gastric paresis and cardiovascular disorders; cyclic guanosine 3',5'-monophosphate (cGMP) | BRISTOL-MYERS SQUIBB CO. | 2003-06-10 | — | — | US | claimed |
| US-20020177587-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225128-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6D 24/4885PDE6A 6/4885 |
| US-20020177587-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6D 27/4885PDE6A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.